Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarvajit Chakravarty

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
American Journal of Respiratory and Critical Care Medicine|January 19, 2008
Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertensionAri L Zaiman, Megan Podowski, Satya Medicherla, et al.
Molecular Pharmacology|April 3, 2007
Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasivenessNicholas J Gaspar, Lingyun Li, Ann M Kapoun, et al.
Bioorganic & Medicinal Chemistry Letters|January 15, 2010
Design and synthesis of piperazine-indole p38 alpha MAP kinase inhibitors with improved pharmacokinetic profilesXuefei Tan, Richland W Tester, Gregory R Luedtke, et al.
Molecular Pharmacology|May 19, 2006
Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expressionAnn M Kapoun, Nicholas J Gaspar, Ying Wang, et al.
Pharmacology|January 8, 2008
Pharmacological properties of SD-282 - an alpha-isoform selective inhibitor for p38 MAP kinaseBruce Koppelman, Heather K Webb, Satyanarayana Medicherla, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2022
Discovery of MDV6058 (PF-06952229), a selective and potent TGFβR1 inhibitor: Design, synthesis and optimizationBrahmam Pujala, Sreekanth A Ramachandran, Mukesh Sonawane, et al.
Bioorganic & Medicinal Chemistry Letters|October 9, 2016
Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitorsPradeep S Jadhavar, Sreekanth A Ramachandran, Eduardo Riquelme, et al.
Bioorganic & Medicinal Chemistry Letters|September 12, 2016
Temozolomide analogs with improved brain/plasma ratios - Exploring the possibility of enhancing the therapeutic index of temozolomideRoopa Rai, Monali Banerjee, Darren H Wong, et al.
Bioorganic & Medicinal Chemistry Letters|April 6, 2017
Design, synthesis and optimization of bis-amide derivatives as CSF1R inhibitorsSreekanth A Ramachandran, Pradeep S Jadhavar, Sandeep K Miglani, et al.
Neuro-Oncology|May 25, 2007
Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma modelThomas-Toan Tran, Martin Uhl, Jing Ying Ma, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
American Journal of Respiratory and Critical Care Medicine|January 19, 2008
Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertensionAri L Zaiman, Megan Podowski, Satya Medicherla, et al.
Molecular Pharmacology|April 3, 2007
Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasivenessNicholas J Gaspar, Lingyun Li, Ann M Kapoun, et al.
Bioorganic & Medicinal Chemistry Letters|January 15, 2010
Design and synthesis of piperazine-indole p38 alpha MAP kinase inhibitors with improved pharmacokinetic profilesXuefei Tan, Richland W Tester, Gregory R Luedtke, et al.
Molecular Pharmacology|May 19, 2006
Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expressionAnn M Kapoun, Nicholas J Gaspar, Ying Wang, et al.
Pharmacology|January 8, 2008
Pharmacological properties of SD-282 - an alpha-isoform selective inhibitor for p38 MAP kinaseBruce Koppelman, Heather K Webb, Satyanarayana Medicherla, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2022
Discovery of MDV6058 (PF-06952229), a selective and potent TGFβR1 inhibitor: Design, synthesis and optimizationBrahmam Pujala, Sreekanth A Ramachandran, Mukesh Sonawane, et al.
Bioorganic & Medicinal Chemistry Letters|October 9, 2016
Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitorsPradeep S Jadhavar, Sreekanth A Ramachandran, Eduardo Riquelme, et al.
Bioorganic & Medicinal Chemistry Letters|September 12, 2016
Temozolomide analogs with improved brain/plasma ratios - Exploring the possibility of enhancing the therapeutic index of temozolomideRoopa Rai, Monali Banerjee, Darren H Wong, et al.
Bioorganic & Medicinal Chemistry Letters|April 6, 2017
Design, synthesis and optimization of bis-amide derivatives as CSF1R inhibitorsSreekanth A Ramachandran, Pradeep S Jadhavar, Sandeep K Miglani, et al.
Neuro-Oncology|May 25, 2007
Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma modelThomas-Toan Tran, Martin Uhl, Jing Ying Ma, et al.
Pageof 4